AtaiBeckley (ATAI) CEO Rao Srinivas Sells ~10.18M Shares in Merger

What Happened
Rao Srinivas (Co‑Founder, CEO and Director) disposed of a total of 10,179,823 shares or share equivalents on September 11, 2026 as part of AtaiBeckley’s merger with Eli Lilly (Merger Sub merged into the company). Under the merger terms, each share converted into $6.75 cash plus one contingent value right (CVR). The cash component equals roughly $68.7 million; the CVRs carry potential additional payments of up to $2.50 each (aggregate potential additional ≈ $25.45M) if specified milestones are achieved. Many of the reported dispositions were derivative awards (stock options and RSUs) that were cancelled and converted into cash and CVRs per the merger agreement.

Key Details

• Transaction date: 2026-09-11 (Effective time of the merger per filing)
• Consideration: $6.75 cash per share + 1 CVR per share (CVRs may pay up to $2.50 each upon milestones)
• Shares/units disposed: 10,179,823 total (mix of common stock and derivative awards)
• Approximate cash received: $6.75 × 10,179,823 ≈ $68.7 million (plus contingent CVR value if earned)
• Post-transaction common shares: common stock was converted at closing (company is now a wholly owned subsidiary); common shares effectively ceased trading
• Notable footnotes: Merger agreement details (F1) and conversion mechanics for common shares (F2), stock options (F3) and RSUs (F4); derivative awards were converted without regard to vesting
• Filing timeliness: Reported with period and filing date of 2026-09-11 (transaction reported promptly in connection with the merger)

Context
This was a merger-driven disposition to the issuer (not an open‑market sale). The cash and CVR treatment is part of the deal mechanics—options and RSUs were canceled and converted into cash and CVRs—so the transaction reflects corporate consideration rather than a standalone insider market sale. CVRs are contingent on future clinical/regulatory milestones, so their eventual value is uncertain.